Search Results: (30 results)

This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.

We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

Researchers at the Mayo Clinic and McGill University are partnering with FORCE on a survey of women who have inherited mutations in BRCA1, BRCA2 or other genes (including PALB2, ATM, CHEK2, and others) related to increased breast cancer risk. We are interested in the effects of testing positive for an inherited mutation on decisions about the timing of pregnancy, breastfeeding, breast cancer screening and risk-reducing surgery. 

The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.  

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Ths study is closed

The Treatment Study is an international research study to better understand breast cancer treatment among individuals with ATM, CHEK2 and PALB2 gene mutations. Participants are asked to complete online or paper study questionnaires (every two years for 10 years) and share their family history, medical, and genetics records.

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

Researchers are conducting an online survey to look into the personal experiences of people who received reclassfied genetic testing results for hereditary cancer gene mutations. 

ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time. ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.

The research laboratory at the Abramson Cancer Center is studying genetic sources of cancer risk and currently has one of the largest collections (also called a registry) of families with known or suspected risk in the world. A number of research projects are performed in collaboration with this registry. Research participants receive a numerical identification number that protects their privacy. Collaborating centers do not have access to personal identifiers such as names and dates of birth because only the numerical identifiers are shared.

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

Researchers at the University of Kentucky are hoping to learn more about the relational experiences of individuals with hereditary breast cancer mutations who have navigated a double mastectomy while in a committed romantic relationship. They are particularly interested in the couples’ experience related to sexual intimacy before and after prophylactic surgical procedures. You do not have to live in Kentucky to participate. 

Our goal is to understand the experiences of people with intellectual disability in regard to screening for cancer, for example colonoscopies for colon cancer and mammograms for breast cancer. For people not being screened, we hope to learn about any barriers faced.

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

This study is to understand the experiences of people who have received a negative genetic test result for a known familial hereditary cancer mutation (i.e., a “true negative” result) and determine what factors influence the presence of survivors’ guilt in these individuals.

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! 

This study is being done to look at how well a combination of three drugs works for the treatment of metastatic colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the metastatic setting. 

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if  pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

Study using acupressure for people experiencing fatigue after ovarian cancer treatment.

Chemotherapy-induced peripheral neuropathy (CIPN) symptoms include numbness combined with tingling sensations, persistent shooting, stabbing, or burning pain even in the absence of an obvious cause, lower extremity muscle weakness, and impaired balance. Resistance exercise has shown promising results; however, the effect of exercise on CIPN remains understudied. This study will look at the effects of gain and balance training and resistance exercise (using bands) on gait, balance, and lower extremity muscle strength after a 16-week home-based exercise program compared to educational materials without an exercise program.

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.

Explore women's lived experiences of sexuality after gynecological cancer treatment(s).

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.

The TALAPRO-3 trial is assessing whether the study drug, talazoparib, is effective and safe when given in combination with enzalutamide as a treatment option for men with metastatic castration-sensitive prostate cancer and a DDR gene alteration.

This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers.  People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.

Modus Outcomes is seeking patients with stage III or IV ovarian cancer to participate in online interviews. We will ask you questions about your symptoms and how ovarian cancer impacts your life. Then, we will ask for feedback on questionnaires used in ovarian cancer studies.